Influence of Chronic Kidney Disease on Cardiac Structure and Function

Current Hypertension Reports

Volumn 17, Issue 9, 2015, Pages

  Matsushita, Kunihiro ^a,b   Ballew, Shoshana H ^a,b   Coresh, Josef ^a,b  

^a JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^b JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

Albuminuria; Cardiac function; Cardiac structure; Chronic kidney disease; Diastolic dysfunction; Glomerular filtration rate; Left ventricular hypertrophy; Renin angiotensin system inhibitors; Systolic dysfunction

Indexed keywords

ALBUMINURIA; CARDIOVASCULAR DISEASE; CARDIOVASCULAR PARAMETERS; CARDIOVASCULAR RISK; CHRONIC KIDNEY DISEASE; COMORBIDITY; DIASTOLE; DISEASE ASSOCIATION; GLOMERULUS FILTRATION RATE; HEART FUNCTION; HEART LEFT VENTRICLE FUNCTION; HEART LEFT VENTRICLE MASS; HEART LEFT VENTRICLE SIZE; HEART LEFT VENTRICLE STRUCTURE; HEART STRUCTURE; HUMAN; KIDNEY DYSFUNCTION; KIDNEY INJURY; MEDICAL LITERATURE; PUBLIC HEALTH SERVICE; REVIEW; SYSTOLE; CHRONIC KIDNEY FAILURE; HYPERTENSION; PATHOLOGY; PATHOPHYSIOLOGY;

BIOLOGICAL MARKER;

ALBUMINURIA; BIOLOGICAL MARKERS; CARDIOVASCULAR DISEASES; GLOMERULAR FILTRATION RATE; HUMANS; HYPERTENSION; RENAL INSUFFICIENCY, CHRONIC;

EID: 84938880247     PISSN: 15226417     EISSN: 15343111     Source Type: Journal    
DOI: 10.1007/s11906-015-0581-x     Document Type: Review

References (81)

1. Matsushita K, van der Velde M, Astor BC, Woodward M, Levey AS, de Jong PE, et al. Association of estimated glomerular filtration rate and albuminuria with all-cause and cardiovascular mortality in general population cohorts: a collaborative meta-analysis. Lancet. 2010;375:2073–81.
2. United States Renal Data System. 2011 USRDS Annual Data Report: Atlas of End-Stage Renal Disease in the United States, National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, MD, 2011. 2011.
3. Gansevoort RT, Correa-Rotter R, Hemmelgarn BR, Jafar TH, Heerspink HJ, Mann JF, et al. Chronic kidney disease and cardiovascular risk: epidemiology, mechanisms, and prevention. Lancet. 2013;382:339–52. Comprehensive review summarizing the contribution of CKD to cardiovascular disease risk.
4. Alonso A, Lopez FL, Matsushita K, Loehr LR, Agarwal SK, Chen LY, et al. Chronic kidney disease is associated with the incidence of atrial fibrillation: the Atherosclerosis Risk in Communities (ARIC) study. Circulation. 2011;123:2946–53.
5. Blecker S, Matsushita K, Kottgen A, Loehr LR, Bertoni AG, Boulware LE, et al. High-normal albuminuria and risk of heart failure in the community. Am J Kidney Dis: Off J Natl Kidney Found. 2011;58:47–55.
6. Kottgen A, Russell SD, Loehr LR, Crainiceanu CM, Rosamond WD, Chang PP, et al. Reduced kidney function as a risk factor for incident heart failure: the atherosclerosis risk in communities (ARIC) study. J Am Soc Nephrol: JASN. 2007;18:1307–15.
7. Matsushita K, Selvin E, Bash LD, Astor BC, Coresh J. Risk implications of the new CKD-EPI equation as compared to the MDRD Study equation for estimated glomerular filtration rate: the Atherosclerosis Risk in Communities (ARIC) Study. Am J Kidney Dis. 2010;55:648–59.
8. Wattanakit K, Folsom AR, Selvin E, Coresh J, Hirsch AT, Weatherley BD. Kidney function and risk of peripheral arterial disease: results from the Atherosclerosis Risk in Communities (ARIC) Study. J Am Soc Nephrol: JASN. 2007;18:629–36.
9. Matsushita K, Coresh J, Sang Y, Chalmers J, Fox C, Guallar E, Jafar T, Jassal SK, Landman GWD, Muntner P, Roderick P, Sairenchi T, Schöttker B, Shankar A, Shlipak M, Tonelli M, Townend J, Zuilen Av, Yamagishi K, Yamashita K, Gansevoort R, Sarnak M, Warnock DG, Woodward M and Ärnlöv J. CKD Prognosis Consortium. Estimated glomerular filtration rate and albuminuria for prediction of cardiovascular outcomes: a collaborative meta-analysis of individual participant data. Lancet Diab Endocrinol. 2015;3:514–525. An international collaborative study demonstrating a more evident improvement for heart failure risk prediction with CKD measures than that for coronary and stroke risk prediction.
10. Levin A, Singer J, Thompson CR, Ross H, Lewis M. Prevalent left ventricular hypertrophy in the predialysis population: identifying opportunities for intervention. Am J Kidney Dis: Off J Natl Kidney Found. 1996;27:347–54.
11. Mathenge RN, McLigeyo SO, Muita AK, Otieno LS. The spectrum of echocardiographic findings in chronic renal failure. East Afr Med J. 1993;70:107–11.
12. National Kidney Foundation. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis: Off J Natl Kidney Found. 2002;39:S1–S266.
13. Verma A, Anavekar NS, Meris A, Thune JJ, Arnold JM, Ghali JK, et al. The relationship between renal function and cardiac structure, function, and prognosis after myocardial infarction: the VALIANT Echo Study. J Am Coll Cardiol. 2007;50:1238–45.
14. Katz DH, Selvaraj S, Aguilar FG, Martinez EE, Beussink L, Kim KY, et al. Association of low-grade albuminuria with adverse cardiac mechanics: findings from the hypertension genetic epidemiology network (HyperGEN) study. Circulation. 2014;129:42–50.
15. Bilge AK, Atilgan D, Onur I, Pamukcu B, Ozcan M, Adalet K. Relationship between left ventricular hypertrophy, hypertensive retinopathy, microalbuminuria and echocardiographic modalities in newly diagnosed hypertensive patients. Int J Cardiovasc Imaging. 2010;26:405–12.
16. Krishnasamy R, Isbel NM, Hawley CM, Pascoe EM, Leano R, Haluska BA, et al. The association between left ventricular global longitudinal strain, renal impairment and all-cause mortality. Nephrol Dial Transplant: Off Publ Eur Dial Transplant Assoc - Eur Ren Assoc. 2014;29:1218–25.
17. Liu YW, Su CT, Huang YY, Yang CS, Huang JW, Yang MT, et al. Left ventricular systolic strain in chronic kidney disease and hemodialysis patients. Am J Nephrol. 2011;33:84–90.
18. Paulus WJ, Tschope C, Sanderson JE, Rusconi C, Flachskampf FA, Rademakers FE, et al. How to diagnose diastolic heart failure: a consensus statement on the diagnosis of heart failure with normal left ventricular ejection fraction by the Heart Failure and Echocardiography Associations of the European Society of Cardiology. Eur Heart J. 2007;28:2539–50.
19. Kannel WB, Doyle JT, McNamara PM, Quickenton P, Gordon T. Precursors of sudden coronary death. Factors related to the incidence of sudden death. Circulation. 1975;51:606–13.
20. Peterson GE, de Backer T, Contreras G, Wang X, Kendrick C, Greene T, et al. Relationship of left ventricular hypertrophy and diastolic function with cardiovascular and renal outcomes in African Americans with hypertensive chronic kidney disease. Hypertension. 2013;62:518–25.
21. Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group. KDIGO 2012 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease. Kidney Int Suppl. 2013;3(1):150.
22. Shah AM, Lam CS, Cheng S, Verma A, Desai AS, Rocha RA, et al. The relationship between renal impairment and left ventricular structure, function, and ventricular-arterial interaction in hypertension. J Hypertens. 2011;29:1829–36. One of the most comprehensive studies regarding echo parameters in their associations with both CKD measures, kidney function and albuminuria.
23. Nguyen MT, Cosson E, Valensi P, Poignard P, Nitenberg A, Pham I. Transthoracic echocardiographic abnormalities in asymptomatic diabetic patients: association with microalbuminuria and silent coronary artery disease. Diabetes Metab. 2011;37:343–50.
24. Schmieder RE, Messerli FH, Garavaglia G, Nunez B. Glomerular hyperfiltration indicates early target organ damage in essential hypertension. JAMA. 1990;264:2775–80.
25. Lim YH, Kim YM, Shin J, Lee CH, Kim JH, Kim MK, et al. Association of heart rate and left ventricular structure in a rural population in Korea. Clin Exp Hypertens (New York, NY: 1993). 2014;36:165–72.
26. Matsumoto M, Io H, Furukawa M, Okumura K, Masuda A, Seto T, et al. Risk factors associated with increased left ventricular mass index in chronic kidney disease patients evaluated using echocardiography. J Nephrol. 2012;25:794–801.
27. Park M, Hsu CY, Li Y, Mishra RK, Keane M, Rosas SE, et al. Associations between kidney function and subclinical cardiac abnormalities in CKD. J Am Soc Nephrol: JASN. 2012;23:1725–34. One of the largest studies regarding the association of reduced kidney function and cardiac structure and function.
28. Lieb W, Mayer B, Stritzke J, Doering A, Hense HW, Loewel H, et al. Association of low-grade urinary albumin excretion with left ventricular hypertrophy in the general population: the MONICA/KORA Augsburg Echocardiographic Substudy. Nephrol Dial Transplant: Off Publ Eur Dial Transplant Assoc - Eur Ren Assoc. 2006;21:2780–7.
29. Perrone RD, Abebe KZ, Schrier RW, Chapman AB, Torres VE, Bost J, et al. Cardiac magnetic resonance assessment of left ventricular mass in autosomal dominant polycystic kidney disease. Clin J Am Soc Nephrol: CJASN. 2011;6:2508–15.
30. Palmieri V, Tracy RP, Roman MJ, Liu JE, Best LG, Bella JN, et al. Relation of left ventricular hypertrophy to inflammation and albuminuria in adults with type 2 diabetes: the strong heart study. Diabetes Care. 2003;26:2764–9.
31. Jensen MT, Sogaard P, Andersen HU, Bech J, Hansen TF, Galatius S, et al. Prevalence of systolic and diastolic dysfunction in patients with type 1 diabetes without known heart disease: the Thousand & 1 Study. Diabetologia. 2014;57:672–80.
32. Zhou J, Cui X, Jin X, Zhou J, Zhang H, Tang B, et al. Association of renal biochemical parameters with left ventricular diastolic dysfunction in a community-based elderly population in China: a cross-sectional study. PLoS One. 2014;9:e88638.
33. Ronco C, Haapio M, House AA, Anavekar N, Bellomo R. Cardiorenal syndrome. J Am Coll Cardiol. 2008;52:1527–39.
34. Kim Y, Matsushita K, Sang Y, Grams ME, Skali H, Shah AM, et al. Association of high-sensitivity cardiac troponin T and natriuretic peptide with incident ESRD: The Atherosclerosis Risk in Communities (ARIC) Study. Am J Kidney Dis: Off J Natl Kidney Found. 2015;65:550–8.
35. Huang M, Matsushita K, Sang Y, Ballew SH, Astor BC, Coresh J. Association of kidney function and albuminuria with prevalent and incident hypertension: the Atherosclerosis Risk in Communities (ARIC) study. Am J Kidney Dis: Off J Natl Kidney Found. 2015;65:58–66.
36. Kuwahara M, Iimori S, Kuyama T, Akita W, Mori Y, Asai T, et al. Effect of anemia on cardiac disorders in pre-dialysis patients immediately before starting hemodialysis. Clin Exp Nephrol. 2011;15:121–5.
37. Jovanovich A, Ix JH, Gottdiener J, McFann K, Katz R, Kestenbaum B, et al. Fibroblast growth factor 23, left ventricular mass, and left ventricular hypertrophy in community-dwelling older adults. Atherosclerosis. 2013;231:114–9.
38. Laflamme MH, Mahjoub H, Mahmut A, Boulanger MC, Larose E, Pibarot P, et al. Parathyroid hormone is associated with the LV mass after aortic valve replacement. Heart (British Cardiac Society). 2014;100:1859–64.
39. Sato B, Yoshikawa D, Ishii H, Suzuki S, Inoue Y, Takeshita K, et al. Relation of plasma indoxyl sulfate levels and estimated glomerular filtration rate to left ventricular diastolic dysfunction. Am J Cardiol. 2013;111:712–6.
40. Wang AY, Fang F, Chan J, Wen YY, Qing S, Chan IH, et al. Effect of paricalcitol on left ventricular mass and function in CKD—the OPERA trial. J Am Soc Nephrol: JASN. 2014;25:175–86.
41. Chue CD, Townend JN, Moody WE, Zehnder D, Wall NA, Harper L, et al. Cardiovascular effects of sevelamer in stage 3 CKD. J Am Soc Nephrol: JASN. 2013;24:842–52.
42. Akaishi M, Hiroe M, Hada Y, Suzuki M, Tsubakihara Y, Akizawa T. Effect of anemia correction on left ventricular hypertrophy in patients with modestly high hemoglobin level and chronic kidney disease. J Cardiol. 2013;62:249–56.
43. Zamboli P, De Nicola L, Minutolo R, Chiodini P, Crivaro M, Tassinario S, et al. Effect of furosemide on left ventricular mass in non-dialysis chronic kidney disease patients: a randomized controlled trial. Nephrol Dial Transplant: Off Publ Eur Dial Transplant Assoc - Eur Ren Assoc. 2011;26:1575–83.
44. Chertow GM, Levin NW, Beck GJ, Depner TA, Eggers PW, Gassman JJ, et al. In-center hemodialysis six times per week versus three times per week. N Engl J Med. 2010;363:2287–300.
45. Vaidya OU, House JA, Coggins TR, Patil H, Vaidya A, Awad A, et al. Effect of renal transplantation for chronic renal disease on left ventricular mass. Am J Cardiol. 2012;110:254–7.
46. El Nahas M. Cardio-Kidney-Damage: a unifying concept. Kidney Int. 2010;78:14–8.
47. Paulus WJ, Tschöpe C. A novel paradigm for heart failure with preserved ejection fraction. J Am Coll Cardiol. 2013;62:263–71.
48. Morigi M, Macconi D, Zoja C, Donadelli R, Buelli S, Zanchi C, et al. Protein overload-induced NF-kappaB activation in proximal tubular cells requires H(2)O(2) through a PKC-dependent pathway. J Am Soc Nephrol: JASN. 2002;13:1179–89.
49. Devereux RB, Dahlof B, Gerdts E, Boman K, Nieminen MS, Papademetriou V, et al. Regression of hypertensive left ventricular hypertrophy by losartan compared with atenolol: the Losartan Intervention for Endpoint Reduction in Hypertension (LIFE) trial. Circulation. 2004;110:1456–62.
50. Blood Pressure Lowering Treatment Trialists’ Collaboration. Effects of different blood-pressure-lowering regimens on major cardiovascular events: results of prospectively-designed overviews of randomised trials. Lancet. 2003;362:1527–35.
51. Kramer CK, Zinman B, Gross JL, Canani LH, Rodrigues TC, Azevedo MJ, et al. Coronary artery calcium score prediction of all cause mortality and cardiovascular events in people with type 2 diabetes: systematic review and meta-analysis. BMJ. 2013;346:f1654.
52. European Society of Hypertension-European Society of Cardiology Guidelines Committee. 2003 European Society of Hypertension-European Society of Cardiology guidelines for the management of arterial hypertension. J Hypertens. 2003;21:1011–53.
53. Lesaffre F, Wynckel A, Nazeyrollas P, Rieu P, Metz D. Echocardiography to predict adverse cardiac and vascular events in patients with severe chronic kidney disease (stage 4): a prospective study. Arch Cardiovasc Dis. 2013;106:220–7.
54. Chen SC, Chang JM, Liu WC, Huang JC, Tsai JC, Lin MY, et al. Echocardiographic parameters are independently associated with increased cardiovascular events in patients with chronic kidney disease. Nephrol Dial Transplant: Off Publ Eur Dial Transplant Assoc - Eur Ren Assoc. 2012;27:1064–70.
55. Payne J, Sharma S, De Leon D, Lu JL, Alemu F, Balogun RA, et al. Association of echocardiographic abnormalities with mortality in men with non-dialysis-dependent chronic kidney disease. Nephrol Dial Transplant: Off Publ Eur Dial Transplant Assoc - Eur Ren Assoc. 2012;27:694–700.
56. Shah AM, Solomon SD. Myocardial deformation imaging: current status and future directions. Circulation. 2012;125:e244–8.
57. Su LJ, Fiehn O, Maruvada P, Moore SC, O’Keefe SJ, Wishart DS, et al. The use of metabolomics in population-based research. Adv Nutr. 2014;5:785–8.
58. Afshinnia F, Spitalewitz S, Chou SY, Gunsburg DZ, Chadow HL. Left ventricular geometry and renal function in hypertensive patients with diastolic heart failure. Am J Kidney Dis: Off J Natl Kidney Found. 2007;49:227–36.
59. Astor BC, Arnett DK, Brown A, Coresh J. Association of kidney function and hemoglobin with left ventricular morphology among African Americans: the Atherosclerosis Risk in Communities (ARIC) study. Am J Kidney Dis: Off J Natl Kidney Found. 2004;43:836–45.
60. Aumann N, Baumeister SE, Werner A, Wallaschofski H, Hannemann A, Nauck M, et al. Inverse association of estimated cystatin C- and creatinine-based glomerular filtration rate with left ventricular mass: Results from the Study of Health in Pomerania. Int J Cardiol. 2013;167:2786–91.
61. Buono F, Crispo S, Pagano G, Rengo G, Petitto M, Grieco F, et al. Determinants of left ventricular hypertrophy in patients with recent diagnosis of essential hypertension. J Hypertens. 2014;32:166–73.
62. Choi SW, Kim HY, Lee YH, Ryu SY, Kweon SS, Rhee JA, et al. eGFR is associated with subclinical atherosclerosis independent of albuminuria: the Dong-gu Study. Atherosclerosis. 2010;212:661–7.
63. Ersboll M, Valeur N, Hassager C, Sogaard P, Kober L. The association between renal impairment and cardiac structure and function in patients with acute myocardial infarction. Am Heart J. 2014;167:506–13.
64. Fedecostante M, Spannella F, Cola G, Espinosa E, Dessi-Fulgheri P, Sarzani R. Chronic kidney disease is characterized by “double trouble” higher pulse pressure plus night-time systolic blood pressure and more severe cardiac damage. PLoS One. 2014;9:e86155.
65. Fesler P, Du Cailar G, Ribstein J, Mimran A. Left ventricular remodeling and renal function in never-treated essential hypertension. J Am Soc Nephrol: JASN. 2003;14:881–7.
66. Han LL, Bai XJ, Lin HL, Sun XF, Chen XM. Association between kidney and cardiac diastolic function in Chinese subjects without overt disease: correlation with ageing and inflammatory markers. Eur J Clin Invest. 2011;41:1077–86.
67. Henry RM, Kamp O, Kostense PJ, Spijkerman AM, Dekker JM, Nijpels G, et al. Mild renal insufficiency is associated with increased left ventricular mass in men, but not in women: an arterial stiffness-related phenomenon—the Hoorn Study. Kidney Int. 2005;68:673–9.
68. Iwashima Y, Horio T, Kamide K, Tokudome T, Yoshihara F, Nakamura S, et al. Additive interaction of metabolic syndrome and chronic kidney disease on cardiac hypertrophy, and risk of cardiovascular disease in hypertension. Am J Hypertens. 2010;23:290–8.
69. Ix JH, Shlipak MG, Chertow GM, Ali S, Schiller NB, Whooley MA. Cystatin C, left ventricular hypertrophy, and diastolic dysfunction: data from the Heart and Soul Study. J Card Fail. 2006;12:601–7.
70. Kramer H, Jacobs Jr DR, Bild D, Post W, Saad MF, Detrano R, et al. Urine albumin excretion and subclinical cardiovascular disease. The Multi-Ethnic Study of Atherosclerosis. Hypertension. 2005;46:38–43.
71. Liu JE, Robbins DC, Palmieri V, Bella JN, Roman MJ, Fabsitz R, et al. Association of albuminuria with systolic and diastolic left ventricular dysfunction in type 2 diabetes: the Strong Heart Study. J Am Coll Cardiol. 2003;41:2022–8.
72. Maunganidze F, Norton GR, Maseko MJ, Libhaber CD, Majane OH, Sareli P, et al. Relationship between glomerular dysfunction and left-ventricular mass independent of haemodynamic factors in a community sample. J Hypertens. 2013;31:568–75. discussion 575.
73. Moran A, Katz R, Jenny NS, Astor B, Bluemke DA, Lima JA, et al. Left ventricular hypertrophy in mild and moderate reduction in kidney function determined using cardiac magnetic resonance imaging and cystatin C: the multi-ethnic study of atherosclerosis (MESA). Am J Kidney Dis: Off J Natl Kidney Found. 2008;52:839–48.
74. Nardi E, Palermo A, Mule G, Cusimano P, Cottone S, Cerasola G. Left ventricular hypertrophy and geometry in hypertensive patients with chronic kidney disease. J Hypertens. 2009;27:633–41.
75. Palatini P, Graniero GR, Mormino P, Mattarei M, Sanzuol F, Cignacco GB, et al. Prevalence and clinical correlates of microalbuminuria in stage I hypertension. Results from the Hypertension and Ambulatory Recording Venetia Study (HARVEST Study). Am J Hypertens. 1996;9:334–41.
76. Patel PC, Ayers CR, Murphy SA, Peshock R, Khera A, de Lemos JA, et al. Association of cystatin C with left ventricular structure and function: the Dallas Heart Study. Circ Heart Fail. 2009;2:98–104.
77. Schou M, Kjaergaard J, Torp-Pedersen C, Hassager C, Gustafsson F, Akkan D, et al. Renal dysfunction, restrictive left ventricular filling pattern and mortality risk in patients admitted with heart failure: a 7-year follow-up study. BMC Nephrol. 2013;14:267.
78. Sonmez O, Vatankulu MA, Tasal A, Bacaksiz A, Ayhan S, Yazici HU, et al. Does estimated glomerular filtration rate have an effect on left ventricular function after ST-elevation myocardial infarction? Echocardiography (Mount Kisco, NY). 2014;31:318–24.
79. Turkbey EB, Backlund JY, Genuth S, Jain A, Miao C, Cleary PA, et al. Myocardial structure, function, and scar in patients with type 1 diabetes mellitus. Circulation. 2011;124:1737–46.
80. Wachtell K, Palmieri V, Olsen MH, Bella JN, Aalto T, Dahlof B, et al. Urine albumin/creatinine ratio and echocardiographic left ventricular structure and function in hypertensive patients with electrocardiographic left ventricular hypertrophy: the LIFE study. Losartan Intervention for Endpoint Reduction. Am Heart J. 2002;143:319–26.
81. Pfeffer MA, McMurray J, Leizorovicz A, Maggioni AP, Rouleau JL, Van De Werf F, et al. Valsartan in acute myocardial infarction trial (VALIANT): rationale and design. Am Heart J. 2000;140:727–50.